Johnson & Johnson Ends Trial of Skin-Disorder Drug Over Adverse Events
Johnson & Johnson (JNJ) terminated a clinical trial of an experimental drug for a skin disorder after two patients in Japan experienced serious drops in infection-fighting white blood cells.